Connect the many factors impacting rare disease care
Our rare-focused pharmacists and nurses work collaboratively and seamlessly to support complex therapies — yet each patient journey has its own twists and turns shaped by numerous care partners and critical patient resources. Our clinical methodologies for rare disease go far beyond traditional specialty pharmacy services, delivering personalized education, coordinated care and multidisciplinary support across every key touchpoint of a care plan – one that is uniquely designed for each patient.
Therapy-based workflows set Biologics apart
At the heart of every Biologics rare disease workflow is a dedicated operational team with an in-depth understanding of each disease state and therapy we support. These therapy-focused teams are a key differentiator for Biologics and a powerful advantage for biopharma partners navigating rare and orphan disease journeys that may not be widely understood by providers, payers, patients or caregivers This team delivers clinical value by providing:
- Deep knowledge of each patient’s diagnosis
- Progression of the disease
- Other specialties that may be involved
- Therapy-specific insights
- Access pathways
- Side effects and management strategies
- Physical and emotional patient needs
- Special considerations for caregivers and families
- Payer protocols
- Denials and appeals
Our teams undergo rigorous training to ensure our clinical methodologies help all stakeholders navigate these highly specialized journeys, including complex access requirements tied to pharmacy and medical billing. We not only educate patients and their families about what to expect — we also work alongside providers to help them navigate payer requirements for rare disease therapies.
Expert appeals support from rare disease nurses
Due to the complexity of rare disease treatment pathways – and limited familiarity among many payers – prior authorization and reimbursement denials are not uncommon. In these situations, Biologics may offer enhanced appeals support for select rare therapies, grounded in a deep understanding of the disease, treatment and patient journey. Access to a knowledgeable rare disease appeals nurse can support timely patient access to therapy.
Risk-based workflows to meet individual needs
Our risk-based care model is Biologics' gold standard for rare and orphan disease journeys. Risk-based care offers highly personalized care plans tailored to the disease, course of therapy and evolving needs of each patient and family.
The role of specialty pharmacy
The journey begins with a “Day Zero” call directly from a specialty pharmacist, who has deep knowledge of the disease state and prescribed therapy. During this call, the pharmacist provides education to the patient and/or caregiver on how and when to administer the medication, proper storage, and potential side effects. They also review the patient’s current medications and supplements to screen for potential drug interactions. A wellness assessment follows to better understand the patient’s emotional well‑being, physical capabilities, and potential risk for non‑adherence.
The nursing handoff
This initial pharmacist call sets the foundation for a personalized, risk‑based care plan that is developed and managed by a registered nurse, who serves as the patient’s primary point of contact for ongoing clinical support. Nurses conduct thoughtfully timed outreach to guide patients and caregivers through complex processes such as reconstitution or injections and provide continued support to help manage challenging dosing schedules, side effects, or other barriers to adherence. Nursing support is dynamically adjusted over time based on clinical risk, treatment milestones, and changing family needs.
Risk Evaluation and Mitigation Strategies (REMS) leadership
Some rare disease therapies are launched with a Food and Drug Administration (FDA)-mandated REMS program that may involve specialized lab monitoring, reproductive safeguards or genetic risk considerations. Since 2005, our REMS pharmacists and nurses have been guiding families and providers through each safety requirement, coordinating with multiple specialists, and documenting all compulsory checkpoints to ensure that stringent protocols are followed and recorded as required. Our biopharma partners rely on Biologics to support patient safety, regulatory compliance and uninterrupted therapy access to REMS-governed pathways.
The nurses have been caring, considerate of my needs and privacy, as well as just downright supportive of answering my every question and caring about my emotional needs.
Pediatric support, from newborns to teens
- Age-appropriate disease and therapy education
- Caregiver training, coaching, and ongoing support
- Emotional and psychosocial support for patients and families
- Practical strategies to balance treatment with school, work, and daily life
- Support managing side effects and complex treatment routines
- Care coordination and communication across multiple specialists
Contact us to learn how we support rare disease therapy implementation.
Frequently asked questions: rare disease support
Once a treatment has been prescribed, how quickly can patients generally begin their course of therapy?
As with most rare and orphan disease treatments, it’s difficult to cite a specific time to treatment. However, our clinical methodologies are intentionally designed to move quickly from the moment a prescription comes in, from obtaining prior authorization to providing education and getting medications into the patient’s hands.
How does Biologics support pediatric patients and their caregivers?
We believe that children – from newborns through high school seniors – should be defined by more than their disease. Beyond supporting the rare specialty therapy itself, we provide comprehensive clinical care and case management that address the real‑life challenges families face. Whether it’s helping a young child navigate complex emotions, supporting an adolescent balancing treatment with school responsibilities, or guiding caregivers as they juggle work, family, and caregiving demands, our individualized care model accounts for these unique circumstances to promote adherence and support positive outcomes for the entire family.
What are some of the key reasons our biopharma partners choose Biologics for programs with a REMS requirement?
With more than 20 years of experience administering REMS programs, including limited distribution drugs, the Biologics team understands the critical importance of following FDA REMS requirements. We have a proven track record of helping biopharma manufacturers demonstrate REMS compliance and keep patient safety at the forefront of the treatment journey, and our in-depth knowledge of protocols for high-risk therapies helps us quickly address paperwork issues or clinical concerns that could impact the course of treatment.
What level of interaction does the Biologics team have with providers?
At the clinical level, Biologics communicates with providers as frequently as needed to ensure patient journeys continue safely and without unnecessary delays. Some interactions are process‑focused, such as resolving expired prior authorizations or obtaining missing lab documentation. Others are clinically driven, including outreach related to side effects or treatment‑related concerns. Whenever a logistical or clinical issue has the potential to impact access, adherence or patient safety, our nurses proactively keep providers informed – using proprietary or third‑party portals when appropriate, and reaching out by phone when matters are urgent.
Extending expertise across rare disease
Purpose‑built support for rare and orphan disease programs navigating complex patient journeys.
Supporting oncology patient journeys
Explore Biologics’ oncology capabilities across access, clinical support and commercialization.
Designed for complex patient journeys
Purpose‑built hub programs supporting oncology, rare disease and cell & gene therapy.